In November 2024, a landmark study published in JAMA Psychiatry changed the conversation about GLP-1 medications and addiction. Researchers analyzed Swedish nationwide registry data for 227,886 individuals with diagnosed alcohol use disorder and found that GLP-1 agonist use — particularly semaglutide — was associated with significantly lower risk of alcohol-related hospitalizations. A second randomized clinical trial, published in February 2025 in the same journal, provided the first prospective evidence that low-dose semaglutide reduces alcohol craving in adults with AUD.
The Swedish Registry Study (Lähteenvuo et al., 2024)
This large-scale cohort study used a within-individual design — comparing each person's hospitalization risk during periods when they were using GLP-1 agonists versus periods when they were not. This design controls for individual-level confounders (genetics, socioeconomic status, baseline health) that plague observational studies.
The results showed that individuals with AUD had markedly lower rates of alcohol-related hospitalization during periods of GLP-1 agonist use. The median follow-up exceeded 8 years, giving the analysis substantial statistical power. Semaglutide showed the strongest signal among the GLP-1 agents studied.
Study Details
Lähteenvuo M, et al. "Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder." JAMA Psychiatry. 2025;82(1):94–98. 227,886 individuals with AUD. Within-individual design. Median follow-up: 8+ years. Finding: significantly reduced alcohol-related hospitalizations during GLP-1 use.
The UNC Randomized Trial (Hendershot et al., 2025)
While the Swedish study was observational, the University of North Carolina trial was a phase 2, double-blind, randomized, placebo-controlled clinical trial — the gold standard for causal inference. 48 adults with AUD received either low-dose semaglutide or placebo for 9 weeks.
The results showed that semaglutide significantly reduced weekly alcohol craving compared to placebo. It also reduced the amount of alcohol consumed during a laboratory self-administration procedure. Interestingly, participants who also smoked showed greater reductions in cigarettes per day — suggesting a cross-addiction effect.
The trial was small (48 participants) and short (9 weeks), which limits the strength of conclusions. But the authors noted the findings "justify larger clinical trials to evaluate GLP-1RAs for alcohol use disorder."
The Mechanism: Why GLP-1s Might Reduce Alcohol Cravings
GLP-1 receptors are expressed throughout the brain's reward circuitry, including the ventral tegmental area (VTA) and nucleus accumbens — the same regions activated by alcohol. Animal studies have demonstrated that GLP-1 agonists reduce dopamine release in response to alcohol, attenuating the rewarding effects of drinking.
The working hypothesis is that GLP-1 medications dampen the hedonic reward signal from alcohol in the same way they dampen the reward signal from food — by modulating mesolimbic dopamine pathways. This doesn't eliminate the desire to drink, but it appears to reduce the intensity of craving and the reinforcing "buzz" from alcohol.
What This Doesn't Mean
Critical context: GLP-1 medications are NOT approved for treating alcohol use disorder. These studies are early-stage — one observational, one small RCT. They justify further research, not clinical prescribing for AUD. If you are struggling with alcohol use disorder, evidence-based treatments exist: naltrexone, acamprosate, behavioral therapy, and support programs. Contact SAMHSA at 1-800-662-4357 for free, confidential support.
A 2025 meta-analysis of the three existing randomized trials found the pooled effect was not statistically significant across all outcomes. The evidence is promising but preliminary. Larger, longer trials are needed before any clinical recommendations can be made.
Interested in GLP-1 for Weight Management?
GLP-1 medications are prescribed for weight management and metabolic health. If you're exploring GLP-1 therapy, these are US-licensed telehealth platforms.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
Injectable semaglutide only. Embody also offers oral tirzepatide gum which is not featured here.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
Sources & References
- Lähteenvuo M, et al. "Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder." JAMA Psychiatry. 2025;82(1):94–98.
- Hendershot CS, et al. "Once-Weekly Semaglutide in Adults With Alcohol Use Disorder." JAMA Psychiatry. 2025;82(4):395–405.
- Sinha B, Ghosal S. "Effects of GLP-1RAs on Alcohol-Related Outcomes: Systematic Review and Meta-Analysis." Addict Sci Clin Pract. 2025.
- SAMHSA. National Helpline: 1-800-662-4357.